Next-generation therapies (NGTs) are playing an increasingly important role in the pipelines and portfolios of leading pharmaceutical companies, driven by market trends like the looming patent cliff and scientific advancements such as the mRNA proof of concept. In particular, mRNA-enabled therapies gained worldwide attention when Pfizer, BioNTech SE and Moderna succeeded in using the technology for the fast development of highly effective COVID-19 vaccines. However, the relative novelty and complexity associated with the development, supply chain, and commercialization of NGTs are putting the industry’s established operating model to the test. Porsche Consulting has identified what should be done to adjust the operating model and become a true NGT champion: ▶️ CHOOSE THE RIGHT PARTNER Gain competitive advantages with smart partnerships. ▶️ BECOME A TECHNOLOGY LEADER Specialize in specific NGT fields and focus. ▶️ SECURE SUPPLY CHAIN Analyze availability of material and define sourcing and manufacturing strategies. ▶️ SET UP MANUFACTURING PARADIGM Focus on efficient automated manufacturing processes with a more decentralized footprint. ▶️ WORK WITH POLICY MAKERS Develop study designs and administration strategies together with key stakeholders. ▶️ ASSUME A COMMERCIAL MINDSET Develop concepts for value-based pricing to increase return on investment. ▶️ PROVIDE END-TO-END SUPPORT Establish platforms to allow a smooth end-to-end patient journey. Find out more about the approach for mastering next-generation therapeutics in the Porsche Consulting Strategy Paper “Pharma’s transformation towards next-generation therapeutics”: https://lnkd.in/emBUAazG #Pharma #NGT #NextGenerationTherapeutics #CellAndGeneTherapy
Super interesting read, both for NGT newcomers who want to know more about the technologies and the associated challenges, but also for pharma companies that want to successfully establish themselves in the field 🚀 I especially love all the practical examples!
Dr. Till Giese
8mo
It was really interesting to see that some big pharma players are already investing a lot in NGTs. Here we are not only talking about mRNA vaccines but also about cell and gene therapies. Overall there are already some good best practices out there on how to grow in this relatively new field.
Thanks for sharing. Valuable insights!
Senior Expert, Life Science Strategy - Porsche Consulting · WEF Global Shaper · Ex-EY-P · Schwarzman Scholar · Astronaut Scholar · Fmr. Student Body President
8moCOVID really was an unprecedented time where science and society collided in a way that brands like Moderna and BioNTech SE became household names. A huge opportunity for accessible, exciting, innovative science - now everyone knows what mRNA is, at least somehow. 🌟 The cool thing is that Next Generation Therapies are even wider. mRNA is hugely exciting, but other approaches like CAR-x cellular therapies and gene therapies will also revolutionize care by enabling more precise treatments. 💊 In the paper, we discuss all NGTs in depth and provide a balanced overview of the main challenges (there are many), as well as the potential solutions and success stories of leading companies. 💪 Excited to see what people think and to continue discussing this interesting topic. 🎉